StemSynergy Therapeutics
"Innovative Stem Cell Research. Targeted Cancer Therapeutics."


The four founders of SSTI hold faculty positions in major medical centers nationwide and have considerable expertise in the developmental pathways that regulate cancer stem cells.  As a group, the founders have 80 years of experience in cancer research, raised over $25M in grant support, and have four patents filed or pending covering both lead-compounds and novel drug targets relevant to cancer stem cells.

Anthony J. Capobianco, PhD

Anthony Capobianco, PhD is Professor and Director of the Molecular Oncology Program in the Dewitt Daughtry Department of Surgery and Professor of Biochemistry and Molecular Biology at the University of Miami Miller School of Medicine, where he also co-leads the Experimental Therapeutics program in the Sylvester Comprehensive Cancer Center. Dr. Capobianco’s lab was among the first to characterize the role of Notch signaling in cancer. His current research focuses on novel points of therapeutic intervention within the Notch signaling network. Dr. Capobianco received his PhD from Boston University and was a postdoctoral fellow at UCSF.

Ethan Lee, MD-PhD

Ethan Lee MD-PhD is Professor in the Department of Cellular & Developmental Biology and Cancer Biology, and Associate Professor in the Department of Pharmacology at Vanderbilt University School of Medicine. His lab focuses on understanding mechanisms of Wnt signaling and the development of novel approaches to target this pathway. His work has lead to the identification of several classes of drugs against the Wnt pathway currently being developed in the pharmaceutical industry. Dr. Lee received his MD and PhD degrees from the University of Texas Southwestern Medical Center followed by postdoctoral training at Harvard Medical School.

David J. Robbins, PhD

David Robbins, PhD is a Professor of Surgery, Biochemistry and Molecular Biology, at the University of Miami Miller School of Medicine. His research focuses on understanding roles for the stem cell regulator Sonic hedgehog (Shh) in both developmental and pathological settings. This goal is approached by elucidating the production and presentation of the secreted ligand Shh, and dissecting signaling pathways downstream of the Shh receptor. These highly complementary and mutually supporting approaches identify mechanisms by which the Shh pathway contributes to human disease. Dr. Robbins has served on the editorial boards of the Journal of Biological Chemistry and Current Cancer Therapy Reviews, and is currently a special editor for Cancer Research. He received his PhD from UT Southwestern, and completed postdoctoral training at UCSF.

William A. Weiss MD-PhD

William A. Weiss MD-PhD is Professor of Neurology, Pediatrics, and Neurological Surgery, University of California, San Francisco CA. He is an expert on developmental therapeutics, focusing on kinase biology, MYC, and in-vivo models of cancer. Dr. Weiss co-leads the Pediatric Malignancies Program within UCSF’s Helen Diller Family Comprehensive Cancer Center, is a senior editor of Cancer Research, and is associate editor of Neuro-Oncology and of Molecular and Cellular Biology. Dr. Weiss received his MD and PhD from the Stanford University School of Medicine, and performed postdoctoral training at UCSF. He completed his clinical training in pediatrics at Boston Children’s Hospital, and in neurology at UCSF.

Scientific Team

SSTI has a multidisciplinary team of scientists.

Meet the Team


Meet the Leadership behind StemSynergy Therapeutics, Inc.

Meet Leadership

Cancer Research

Targeting the developmental pathways that drive cancer.

Cancer Research